MedTrace Logo

Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

NCT06155955 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-03-05

No results posted yet for this study

Summary

* To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration
* To study pharmacokinetic, side effect of low dose Emicizumab

Conditions

  • Severe Hemophilia A Without Inhibitor
  • Joint Bleed

Interventions

DRUG

"Emicizumab", "HEMLIBRA®"

low dose

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • NUCHANUN KESSAKORN · King Chulalongkorn Memorial Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-22
Primary Completion
2024-03-21
Completion
2024-06-21

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06155955 on ClinicalTrials.gov